menu
    • menu

    Company profile for AffaMed Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AffaMed Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs in ophthalmology, neurology and psychiatric disorders for patients in Greater China and around the world. The management team of AffaMed Therapeutics has deep industry expertise and an extensive track record in high-quality clinical de...
    AffaMed Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs in ophthalmology, neurology and psychiatric disorders for patients in Greater China and around the world. The management team of AffaMed Therapeutics has deep industry expertise and an extensive track record in high-quality clinical development, regulatory affairs, CMC, business development, and operations both in China and with leading global pharmaceutical companies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AffaMed TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    450 Lexington Avenue, Suite 39B, New York, NY 10017
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://affamed.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/affamed-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AffaMed Therapeutics Announces NDA Acceptance by HSA for DEXTENZA
    AffaMed Therapeutics Announces NDA Acceptance by HSA for DEXTENZA

    19 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-new-drug-application-acceptance-by-singapore-health-sciences-authority-hsa-for-dextenza-for-treatment-of-ocular-inflammation-and-pain-following-ophthalmic-surgery-and-ocular-itching-associated-wi-302064649.html

    PR NEWSWIRE
    19 Feb 2024
    Share Share
    AffaMed Therapeutics Announces First Patient Treated in Ph 3 Trial for DEXTENZA
    AffaMed Therapeutics Announces First Patient Treated in Ph 3 Trial for DEXTENZA

    20 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-first-patient-treated-in-phase-3-registrational-clinical-trial-in-mainland-china-for-dextenza-for-the-treatment-of-ocular-inflammation-and-pain-following-ophthalmic-surgery-301931587.html

    PR NEWSWIRE
    20 Sep 2023
    Share Share
    Vistagen Reports Positive Results from Phase 3 Trial of Fasedienol Nasal Spray
    Vistagen Reports Positive Results from Phase 3 Trial of Fasedienol Nasal Spray

    10 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-partner-vistagen-reports-positive-top-line-results-from-phase-3-palisade-2-trial-of-fasedienol-ph94b-nasal-spray-in-social-anxiety-disorder-301897671.html

    PR NEWSWIRE
    10 Aug 2023
    Share Share
    AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Cataract Surgery Patients
    AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Cataract Surgery Patients

    31 May 2023

    // ASIAONE

    https://www.asiaone.com/business/affamed-therapeutics-announces-completion-patient-enrollment-real-world-study-china

    ASIAONE
    31 May 2023
    Share Share
    Prof. Roger D. Kornberg will be joining Tissue Dynamics' advisory board
    Prof. Roger D. Kornberg will be joining Tissue Dynamics' advisory board

    31 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/prof-roger-d-kornberg-chemistry-nobel-laureate-will-be-joining-tissue-dynamics-advisory-board-301838660.html

    PR NEWSWIRE
    31 May 2023
    Share Share
    AffaMed Announces Completion of Enrollment in Study Evaluating Efficacy of DEXTENZA
    AffaMed Announces Completion of Enrollment in Study Evaluating Efficacy of DEXTENZA

    31 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-completion-of-patient-enrollment-in-the-real-world-study-in-china-evaluating-the-safety-and-efficacy-of-dextenza-in-cataract-surgery-patients-301838072.html

    PR NEWSWIRE
    31 May 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search